The dosing framework on this page is based on the published Phase 2 trial (Jastreboff et al., 2023, NEJM ) and the Rosenstock et al
In meeting rooms and newspapers across Massachusetts, insurers revealed that GLP-1 drugs made up nearly 20% of their total pharmacy spending in 2024, calling them the single largest driver of its rising costs
Our State of the Art Testing Many patients have a difficult time losing weight due to a combination of thyroid, neurotransmitter, adrenal, nutritional and other hormonal issues
To establish the functional significance of these findings, we next tested the ability of GLP-1(2836) to prevent cytotoxicity in an in vitro model of oxidative stress (38)
Bupropion for Depression Major depressive disorder (MDD) is a common indication for bupropion
Even within the current landscape, some people respond better to one medication over another based on their individual side effect profile